Drug Discovery for Inflammatory Bowel Disease

Our lead pipeline program is an antibody directed towards the target TREM1 for inflammatory bowel disease. We have a sample collaboration with Oxford University that's built to patients with inflammatory bowel disease, ulcerative colitis and Crohn's disease who are receiving humira as first line biologics therapy. And we analyzed their myeloid populations to look at what the differences were between responders and non-responders to anti-TNF therapy. By blocking this, we think that we can actually interrupt a cycle of continued, repeated, exaggerated inflammation in the gut of patients with IBD.